Department of Radiology, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Liaoning 110001, China.
Biomed Res Int. 2017;2017:6049480. doi: 10.1155/2017/6049480. Epub 2017 Aug 1.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and confers a poor prognosis. Novel diagnostic or prognostic biomarkers and effective therapeutic targets for HCCs are urgently needed. Currently, dozens of long noncoding RNAs (lncRNAs) have been identified as playing critical roles in cancer development and progression. Advanced studies have shown that several well-known lncRNAs are dysregulated in HCC tissue as compared to adjacent noncancerous tissue. Furthermore, highly stable cell-free circulating nucleic acids (cfCNAs), including lncRNAs, aberrantly expressed in the plasma of HCC patients, have been detected. In this review, we focus on the most extensively investigated lncRNAs in HCC and discuss the potential of HCC-related lncRNAs as novel biomarkers for early diagnosis and prognosis.
肝细胞癌 (HCC) 是全球最常见的癌症之一，预后不良。目前迫切需要新型的 HCC 诊断或预后生物标志物和有效的治疗靶点。目前，已经确定了数十种长链非编码 RNA (lncRNA) 在癌症的发生和发展中发挥关键作用。深入研究表明，与相邻的非癌组织相比，几种众所周知的 lncRNA 在 HCC 组织中失调。此外，在 HCC 患者的血浆中检测到高度稳定的无细胞循环核酸 (cfCNA)，包括 lncRNA，这些核酸异常表达。在这篇综述中，我们重点介绍 HCC 中研究最广泛的 lncRNA，并讨论 HCC 相关 lncRNA 作为早期诊断和预后的新型生物标志物的潜力。
